Richard E. Buller, MD, PhD

Richard E. Buller, MD, PhD

Richard Buller, M.D, Ph.D was recently appointed as Head of Oncology Clinical Development at Pfizer following three years as Vice President of Translational Oncology. His former group was responsible for development of biomarker and companion diagnostic clinical strategies as well as proof of mechanism/pharmacology for drug candidates.  Recent success is reflected by the approval of crizotinib for the treatment of ALK positive NSCLC. 

Kenneth Buetow, Ph.D.

Kenneth Buetow, Ph.D.

Dr. Ken Buetow is a human genetics and genomics researcher who leverages computational tools to understand complex traits such as cancer, liver disease, and obesity.  Dr. Buetow currently serves as Director of Computational Sciences and Informatics program for Complex Adaptive Systems at Arizona State University (CAS@ASU) and is a professor in the School of Life Sciences in ASU’s College of Liberal Arts and Sciences.  

Martha Brumfield, Ph.D.

Martha Brumfield, Ph.D.

Martha A. Brumfield, PhD, is President and Chief Executive Officer of Critical Path Institute, an Arizona based non-profit (501(c) 3).  In this role, Brumfield leads the institute in its mission to catalyze the development of new tools to advance medical product innovation and regulatory science which is accomplished by leading teams that share data, knowledge and expertise resulting in sound, consensus based science.

Steve Broadbent, MBA

Steve Broadbent, MBA

Steve Broadbent is the Chief Operating Officer for the Critical Path Institute (C-Path), a non-profit organization formed by the Food and Drug Administration, SRI International, and the University of Arizona to accelerate the development of safe, innovative medicines.  This is accomplished by forming and managing seven consortia consisting of nearly 1000 scientists and clinicians from 41 bioscience and pharmaceutical companies, government agencies, patient groups, and academia to develop and qualify tools and processes for use in drug development. 

John (Jack) C. Bloom, VMD, PhD

John (Jack) C. Bloom, VMD, PhD

John C. Bloom holds a B.S. degree in biology from the University of Pittsburgh and doctorates in veterinary medicine and experimental hematology from the University of Pennsylvania. He completed his postdoctoral training at Jefferson Medical College in hematology/oncology and served on the Faculty of the University of Pennsylvania School of Veterinary Medicine as Chief, Clinical Laboratory Medicine, before joining Smith Kline & French Laboratories as Associate Director of Pathology.

Anahita Bhathena, Ph.D.

Anahita Bhathena, Ph.D.

Dr. Anahita Bhathena is an Associate Director of Cancer Biomarkers for AbbVie Prior to the spin out of AbbVie from Abbott, who led the Tumor Genomics and Cancer Biomarkers groups, with responsibility for developing and implementing biomarker and personalized medicine strategies to increase the probability of success of the oncology pipeline. She also led a number of external academic and industry collaborations pertaining to pharmacogenetic and biomarker research.

Donald A Berry, Ph.D.

Donald A Berry, Ph.D.

Donald Berry is a professor in the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. He was founding Chair of this department in 1999 and founding Head of the Division of Quantitative Sciences, including the Department of Bioinformatics and Computational Biology, in 2006. Dr. Berry received a Ph.D. in statistics from Yale University, and previously served on the faculties of the University of Minnesota and Duke University. He held endowed faculty positions at Duke University and at M.D. Anderson.

Michael E. Berens, Ph.D.

Michael E. Berens, Ph.D.

In addition to his roles as Deputy Director for Research Resources at TGen, Dr. Berens serves as Director of the Cancer and Cell Biology Division and Professor in the Brain Tumor Unit.  Dr. Berens’ academic career has included appointments at the University of Zurich, the Bowman Gray School of Medicine of Wake Forest University, the University of California at San Francisco, and the Barrow Neurological Institute.  At BNI, he served for 12 years as Senior Investigator and Director of Neurology Research.

Valerie Barlow, DVM, PhD, DACVP

Valerie Barlow, DVM, PhD, DACVP

Dr. Valerie G. Barlow holds a DVM and Ph.D., and is a Diplomate of the American College of Veterinary Pathologists (clinical pathology). She is currently the Lead of the Translational Science and Biomarker Development group at Genzyme, a Sanofi Company, in Framingham, MA. Responsibilities in her current position include managing the biomarker assay development group, providing comprehensive translational support for projects, coordinating biomarker development processes for the Translational Medicine Unit, as well as providing clinical pathology support for the Disposition, Safety and Animal Research Scientific Core Platform. After obtaining her veterinary degree in Toulouse, France, Valerie went to Colorado State University where she completed a residency in Veterinary Clinical Pathology and obtained a Ph.D. in Pathology. She then joined Aventis, a Sanofi legacy company, as a Veterinary Clinical Pathologist in France. Valerie held a similar position when she moved back to the US and became the Head of the Biomarker/Clinical Pathology laboratory when relocated to Bridgewater, NJ. Most recently, she joined the newly formed Translational Medicine Unit at Genzyme. Throughout her career, Valerie has been involved with biomarkers, from preclinical safety biomarkers (her laboratory provided data for the ILSI consortium) to clinical biomarkers; from assay development to sample analysis under GLP conditions. She is one of the Sanofi representatives for C-Path and the FNIH Biomarker Consortium. Prior to her move to Massachusetts, Valerie was an Adjunct Professor the University of Pennsylvania School of Veterinary Medicine. She likes to spend her free time with family, running after her rambunctious 5-year-old boy, riding her Harley with her husband, and trying new recipes with friends. 

Anna D. Barker, Ph.D.

Anna D. Barker, Ph.D.

Dr. Barker direct efforts in transformative knowledge networks at ASU – specifically directed toward the development of new research models that leverage convergent knowledge, innovative teams and novel funding approaches to better prevent and treat acute and chronic diseases.  She also serves as Co-Director of Complex Adaptive Systems at ASU which serves as an organizing construct to understand and solve multi-dimensional problems in the biological and social and sciences.

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS